T
TREVI THERAPEUTICS INC
NASDAQ: TRVI (Trevi Therapeutics, Inc.)
最近更新时间: 4小时之前5.95
0.00 (0.00%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Trevi Therapeutics, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
1.4
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | -1.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.38 |
|
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 0.75% |
| 机构持股比例 | 75.65% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 25.00 (Cantor Fitzgerald, 320.17%) | 购买 |
| 中 | 22.50 (278.15%) | |
| 低 | 21.00 (HC Wainwright & Co., 252.94%) | 购买 |
| 21.00 (D. Boral Capital, 252.94%) | 购买 | |
| 平均值 | 22.75 (282.35%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 6.19 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Cantor Fitzgerald | 01 Jul 2025 | 25.00 (320.17%) | 购买 | 5.70 |
| D. Boral Capital | 02 Jun 2025 | 21.00 (252.94%) | 购买 | 6.32 |
| HC Wainwright & Co. | 28 May 2025 | 21.00 (252.94%) | 购买 | 6.26 |
| Needham | 20 May 2025 | 24.00 (303.36%) | 购买 | 6.47 |
| 08 Apr 2025 | 24.00 (303.36%) | 购买 | 5.30 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合